Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-22

Nuvalent (NUVL)

CEO James Porter was paid $11,393,602 in fiscal year 2025, ↓ down 34.1% from fiscal year 2024, the 30th percentile of its disclosed peer group (SEC filing 0001861560-26-000013 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$11,393,602 ↓
James Porter total, FY2025
30th
CEO pay percentile vs peers
21:1
CEO-to-median pay ratio
97.47%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- James Porter (President and Chief Executive Officer), FY2025 total compensation $11,393,602 (base salary $652,100) [exec_comp, SEC accession 0001861560-26-000013, filed 2026-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

NUVL's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
James Porter$652,100$0$4,392,563$5,857,906$469,512$0$21,521$11,393,602
President and Chief Executive Officer
Christopher Turner520,10001,464,1881,952,635280,854021,5214,239,298
Chief Medical Officer
Alexandra Balcom475,50001,464,1881,952,635256,770021,5214,170,614
Chief Financial Officer and Treasurer
Darlene Noci467,40001,464,1881,952,635252,396021,5214,158,140
Chief Development Officer
Deborah Miller467,00001,464,1881,952,635252,180021,5214,157,524
Chief Legal Officer and Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
James Porter$11,393,602$17,279,869$9,376,872↓ −5,886,267
Christopher Turner4,239,2985,550,9403,603,207↓ −1,311,642
Alexandra Balcom4,170,6145,486,5903,541,647↓ −1,315,976
Darlene Noci4,158,140———
Deborah Miller4,157,5245,461,540—↓ −1,304,016

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Nuvalent's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper NUVL reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against NUVL
9 companies name NUVL as a compensation peer

Each company listed discloses NUVL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NUVL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Alexandra BalcomCFO$4,170,614
Christopher TurnerChief Medical Officer$4,239,298
Darlene NociChief Development Officer$4,158,140
James PorterCEO$11,393,602
Deborah MillerGeneral Counsel$4,157,524
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Andrew A. F. Hack, M.D., Ph.DFormer director (through FY2025)$24,285
Anna ProtopapasIndependent Director$485,432
Cameron A. Wheeler, Ph.DIndependent Director$454,762
Christy OligerIndependent Director$627,666
Emily Drabant Conley, Ph.DFormer director (through FY2025)$49,499
Gary Gilliland, M.D., Ph.DFormer director (through FY2025)$322,222
Grant C. BogleIndependent Director$449,927
Joseph Pearlberg, M.D., Ph.DIndependent Director$446,932
Matthew Shair, Ph.DFormer director (through FY2025)$639,421
Michael L. Meyers, M.D., Ph.DIndependent Director$451,932
Ron SquarerIndependent Director$602,452
Sapna Srivastava, Ph.DIndependent Director$461,932
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
James PorterDirector2026-05-04A30,000$19$567,900CommonForm 4 ↗
James PorterDirector2026-05-04D30,00000Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-05-04D2,111103217,180CommonForm 4 ↗
James PorterDirector2026-05-04D17,3531021,771,741CommonForm 4 ↗
James PorterDirector2026-05-04D7,429101753,895CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,300106138,138CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D5,50000Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D90010897,326CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D1,530107164,399CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D5,50000Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,178108127,236CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D1,401106148,954CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D1,669109182,422CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28A5,500737,895CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,422107152,623CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D10011010,976CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,500109163,950CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28A5,50028153,175CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D9609591,075CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D20010420,768CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D27910228,399CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D2,588101260,482CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D3,133100312,861CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D9009887,912CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D2,17096208,298CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01A11,430778,753CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D11,43000Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D1,20099118,284CommonForm 4 ↗
James PorterDirector2026-06-08D30,00000Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-06-08D3,03690272,117CommonForm 4 ↗
James PorterDirector2026-06-08D14,469891,284,703CommonForm 4 ↗
James PorterDirector2026-06-08D12,495881,099,185CommonForm 4 ↗
James PorterDirector2026-06-08A30,00019567,900CommonForm 4 ↗
Dividend-equivalent accruals2026-06-09—685——1 insider, 1 accrual row
Darlene NociChief Development Officer2026-06-09D10,00000Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09D20,0001232,456,200CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09A9,31519176,333CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09A10,000110,800CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09D9,31500Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09A68574,720CommonForm 4 ↗
Grant C. BogleDirector2026-06-16A3,44400CommonForm 4 ↗
Michael L. MeyersDirector2026-06-16A3,44400CommonForm 4 ↗
Christy OligerDirector2026-06-16A3,44400CommonForm 4 ↗
Anna ProtopapasDirector2026-06-16A3,44400CommonForm 4 ↗
Ron SquarerDirector2026-06-16A3,44400CommonForm 4 ↗
Sapna SrivastavaDirector2026-06-16A3,44400CommonForm 4 ↗
Cameron WheelerDirector2026-06-16A3,44400Common, indirectForm 4 ↗
James E. FlynnDirector2026-06-16A3,44400Common, indirectForm 4 ↗
Darlene NociChief Development Officer2026-06-29A5,50028153,175CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-29D5,50000Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-29D5,500124679,305CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01A6,04619114,451CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01D5,38400Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01D11,4301241,412,519CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01A5,384737,096CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01D13,85400Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01D9,14600Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01D23,0001242,842,570CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01A13,854721,002,337CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01A9,14619173,134CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01D6,04600Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-06D30,0001243,711,600CommonForm 4 ↗
James PorterDirector2026-07-06D30,00000Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-06A30,00019567,900CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-09D2,111124261,363CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D31,5301243,909,720CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D5,146124638,104Common, indirectForm 4 ↗
Grant C. BogleDirector2026-07-15D5,577——CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D40,000——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D3,444——CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D47,500——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D14,350——CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D18,5341242,298,216CommonForm 4 ↗
James PorterDirector2026-07-15D33,423——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D121,350——CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D41,100——CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D5,146124638,104CommonForm 4 ↗
James E. FlynnDirector2026-07-15D5,146124638,104CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D3,444——Common, indirectForm 4 ↗
Grant C. BogleDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Grant C. BogleDirector2026-07-15D4,851——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D5,146124638,104CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D75,154——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D61,000——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D72,608——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15A14,35000CommonForm 4 ↗
James PorterDirector2026-07-15D46,250——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D112,500——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D131,494——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D118,686——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D867,172——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D49,401——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D508,942——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D40,025——CommonForm 4 ↗
James PorterDirector2026-07-15A40,02500CommonForm 4 ↗
James PorterDirector2026-07-15D203,52912425,237,596CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D18,600——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D9,900——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D8,309——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D2,113——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D14,350——CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15A14,35000CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D41,100——CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D22,3931242,776,732CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D19,000——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D12,025——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D15,052——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D17,848——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D8,333——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D731——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15A7,12000CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D29,433——CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D21,0921242,615,408CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D33,646——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D81,329——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D21,259——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D15,112——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D6,091——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D216——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D14,350——CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15A14,35000CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D17,0171242,110,108CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D47,500——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D144,200——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D2,835——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D14,350——CommonForm 4 ↗
Ron SquarerDirector2026-07-15D4,418——Derivative, Class A CommonForm 4 ↗
Ron SquarerDirector2026-07-15D6,281——CommonForm 4 ↗
Christy OligerDirector2026-07-15D6,119——Derivative, Class A CommonForm 4 ↗
Christy OligerDirector2026-07-15D6,091——CommonForm 4 ↗
Christy OligerDirector2026-07-15D1,324124164,176CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D68,500——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D3,444——CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D33,646——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D84,200——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D22,933——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D8,016——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D131,637——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D14,350——CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D44,4331245,509,692CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D40,000——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D8,361——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D3,444——CommonForm 4 ↗
James E. FlynnDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D43,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D43,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D2,717,627124336,985,748Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D2,717,627124336,985,748Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D3,444124427,056CommonForm 4 ↗
James E. FlynnDirector2026-07-15D5,146124638,104CommonForm 4 ↗
James E. FlynnDirector2026-07-15D650,00012480,600,000Common, indirectForm 4 ↗
James E. FlynnDirector2026-07-15D8,299,2251241,029,103,900Common, indirectForm 4 ↗
James E. FlynnDirector2026-07-15D8,299,2251241,029,103,900Common, indirectForm 4 ↗
Cameron WheelerDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D3,258——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D41,100——CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D107,000——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D303,105——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15A14,35000CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D41,100——CommonForm 4 ↗
James PorterDirector2026-07-15D161,100——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D43,000——Derivative, Class A CommonForm 4 ↗
Grant C. BogleDirector2026-07-15D3,714124460,536CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D41,100——CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D21,073——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D8,000——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D7,120——CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15A14,35000CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D5,146124638,104CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 200 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
James PorterDirector2026-05-04A30,000$19$567,900CommonForm 4 ↗
James PorterDirector2026-05-04D30,00000Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-05-04D2,111103217,180CommonForm 4 ↗
James PorterDirector2026-05-04D17,3531021,771,741CommonForm 4 ↗
James PorterDirector2026-05-04D7,429101753,895CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,300106138,138CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D5,50000Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D90010897,326CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D1,530107164,399CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D5,50000Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,178108127,236CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D1,401106148,954CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28D1,669109182,422CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-05-28A5,500737,895CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,422107152,623CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D10011010,976CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28D1,500109163,950CommonForm 4 ↗
Darlene NociChief Development Officer2026-05-28A5,50028153,175CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D9609591,075CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D20010420,768CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D27910228,399CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D2,588101260,482CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D3,133100312,861CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D9009887,912CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D2,17096208,298CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01A11,430778,753CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D11,43000Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-06-01D1,20099118,284CommonForm 4 ↗
James PorterDirector2026-06-08D30,00000Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-06-08D3,03690272,117CommonForm 4 ↗
James PorterDirector2026-06-08D14,469891,284,703CommonForm 4 ↗
James PorterDirector2026-06-08D12,495881,099,185CommonForm 4 ↗
James PorterDirector2026-06-08A30,00019567,900CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09D68500Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09D10,00000Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09D20,0001232,456,200CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09A9,31519176,333CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09A10,000110,800CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09D9,31500Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-09A68574,720CommonForm 4 ↗
Grant C. BogleDirector2026-06-16A3,44400CommonForm 4 ↗
Michael L. MeyersDirector2026-06-16A3,44400CommonForm 4 ↗
Christy OligerDirector2026-06-16A3,44400CommonForm 4 ↗
Anna ProtopapasDirector2026-06-16A3,44400CommonForm 4 ↗
Ron SquarerDirector2026-06-16A3,44400CommonForm 4 ↗
Sapna SrivastavaDirector2026-06-16A3,44400CommonForm 4 ↗
Cameron WheelerDirector2026-06-16A3,44400Common, indirectForm 4 ↗
James E. FlynnDirector2026-06-16A3,44400Common, indirectForm 4 ↗
Darlene NociChief Development Officer2026-06-29A5,50028153,175CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-29D5,50000Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-06-29D5,500124679,305CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01A6,04619114,451CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01D5,38400Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01D11,4301241,412,519CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01A5,384737,096CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01D13,85400Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01D9,14600Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01D23,0001242,842,570CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01A13,854721,002,337CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-01A9,14619173,134CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-01D6,04600Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-06D30,0001243,711,600CommonForm 4 ↗
James PorterDirector2026-07-06D30,00000Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-06A30,00019567,900CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-09D2,111124261,363CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D31,5301243,909,720CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D5,146124638,104Common, indirectForm 4 ↗
Grant C. BogleDirector2026-07-15D5,577——CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D40,000——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D3,444——CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D47,500——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D14,350——CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D18,5341242,298,216CommonForm 4 ↗
James PorterDirector2026-07-15D33,423——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D121,350——CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D41,100——CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D5,146124638,104CommonForm 4 ↗
James E. FlynnDirector2026-07-15D5,146124638,104CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D3,444——Common, indirectForm 4 ↗
Grant C. BogleDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Grant C. BogleDirector2026-07-15D4,851——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D5,146124638,104CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D75,154——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D61,000——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D72,608——Derivative, Class A CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15A14,35000CommonForm 4 ↗
James PorterDirector2026-07-15D46,250——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D112,500——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D131,494——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D118,686——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D867,172——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D49,401——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D508,942——Derivative, Class A CommonForm 4 ↗
James PorterDirector2026-07-15D40,025——CommonForm 4 ↗
James PorterDirector2026-07-15A40,02500CommonForm 4 ↗
James PorterDirector2026-07-15D203,52912425,237,596CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D18,600——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D9,900——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D8,309——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D2,113——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D14,350——CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15A14,35000CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D41,100——CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D22,3931242,776,732CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D19,000——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D12,025——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D15,052——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D17,848——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D8,333——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D731——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15A7,12000CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D29,433——CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D21,0921242,615,408CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D33,646——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D81,329——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D21,259——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D15,112——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D6,091——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D216——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D14,350——CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15A14,35000CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D17,0171242,110,108CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D47,500——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D144,200——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D2,835——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D14,350——CommonForm 4 ↗
Ron SquarerDirector2026-07-15D4,418——Derivative, Class A CommonForm 4 ↗
Ron SquarerDirector2026-07-15D6,281——CommonForm 4 ↗
Christy OligerDirector2026-07-15D6,119——Derivative, Class A CommonForm 4 ↗
Christy OligerDirector2026-07-15D6,091——CommonForm 4 ↗
Christy OligerDirector2026-07-15D1,324124164,176CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D68,500——Derivative, Class A CommonForm 4 ↗
Sapna SrivastavaDirector2026-07-15D3,444——CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D37,500——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D33,646——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D84,200——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D22,933——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D8,016——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D131,637——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D14,350——CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D44,4331245,509,692CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D40,000——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D8,361——Derivative, Class A CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D3,444——CommonForm 4 ↗
James E. FlynnDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D4,147——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D3,789——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D43,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D43,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D2,717,627124336,985,748Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D2,717,627124336,985,748Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D3,444124427,056CommonForm 4 ↗
James E. FlynnDirector2026-07-15D5,146124638,104CommonForm 4 ↗
James E. FlynnDirector2026-07-15D650,00012480,600,000Common, indirectForm 4 ↗
James E. FlynnDirector2026-07-15D8,299,2251241,029,103,900Common, indirectForm 4 ↗
James E. FlynnDirector2026-07-15D8,299,2251241,029,103,900Common, indirectForm 4 ↗
Cameron WheelerDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
James E. FlynnDirector2026-07-15D20,000——Derivative, Class A CommonForm 4 ↗
Anna ProtopapasDirector2026-07-15D15,000——Derivative, Class A CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D3,258——Derivative, Class A CommonForm 4 ↗
Darlene NociChief Development Officer2026-07-15D41,100——CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D107,000——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D303,105——Derivative, Class A CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15A14,35000CommonForm 4 ↗
Alexandra BalcomChief Financial Officer2026-07-15D41,100——CommonForm 4 ↗
James PorterDirector2026-07-15D161,100——Derivative, Class A CommonForm 4 ↗
Cameron WheelerDirector2026-07-15D43,000——Derivative, Class A CommonForm 4 ↗
Grant C. BogleDirector2026-07-15D3,714124460,536CommonForm 4 ↗
Deborah MillerChief Legal Officer2026-07-15D41,100——CommonForm 4 ↗
Henry E. PelishChief Scientific Officer2026-07-15D21,073——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D8,000——Derivative, Class A CommonForm 4 ↗
Benjamin LaneSee Remarks2026-07-15D7,120——CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15D17,500——Derivative, Class A CommonForm 4 ↗
Christopher TurnerChief Medical Officer2026-07-15A14,35000CommonForm 4 ↗
Michael L. MeyersDirector2026-07-15D5,146124638,104CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
James PorterRSU2025-01-06——56,250—$4,392,563
Alexandra BalcomRSU2025-01-06——18,750—1,464,188
Deborah MillerRSU2025-01-06——18,750—1,464,188
James PorterOPTION2025-01-06——112,500—5,857,906
Darlene NociRSU2025-01-06——18,750—1,464,188
Christopher TurnerRSU2025-01-06——18,750—1,464,188
Darlene NociOPTION2025-01-06——37,500—1,952,635
Alexandra BalcomOPTION2025-01-06——37,500—1,952,635
Christopher TurnerOPTION2025-01-06——37,500—1,952,635
Deborah MillerOPTION2025-01-06——37,500—1,952,635
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
James Porter$4,392,563$0$5,857,9060.0%
Alexandra Balcom1,464,18801,952,6350.0%
Deborah Miller1,464,18801,952,6350.0%
Darlene Noci1,464,18801,952,6350.0%
Christopher Turner1,464,18801,952,6350.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Christopher TurnerRSU18,750—$1,886,063
Christopher TurnerOption39,05427.85—
Christopher TurnerRSU22,200—2,233,098
Christopher TurnerOption24,74072.35—
Alexandra BalcomRSU18,750—1,886,063
Alexandra BalcomPSU5,600—563,304
Alexandra BalcomOption2,22918.93—
Deborah MillerOption24,74072.35—
James PorterRSU75,200—7,564,368
Alexandra BalcomOption24,74072.35—
Alexandra BalcomOption39,05427.85—
Alexandra BalcomRSU22,200—2,233,098
Deborah MillerPSU5,600—563,304
Christopher TurnerOption1,16218.93—
Christopher TurnerOption28,90678.09—
James PorterOption83,90672.35—
James PorterOption6,88318.93—
Deborah MillerOption2,22918.93—
James PorterOption113,96127.85—
James PorterOption86,71978.09—
Deborah MillerOption39,05427.85—
Deborah MillerRSU22,200—2,233,098
Alexandra BalcomOption1,16218.93—
James PorterRSU56,250—5,658,188
Alexandra BalcomOption28,90678.09—
Alexandra BalcomOption8,33314.4—
Deborah MillerRSU18,750—1,886,063
James PorterPSU16,900—1,699,971
Christopher TurnerOption8,33314.4—
Deborah MillerOption28,90678.09—
Christopher TurnerPSU5,600—563,304
Christopher TurnerOption2,22918.93—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to attract and retain qualified and talented executives, motivate such executives to achieve our corporate goals and reward them for short- and long-term performance with a simple and clear compensation structure.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1668,898,7111,786,46517,92697.47%Passed
20252025-06-1853,520,19210,356,8872,49883.79%Passed
20242024-06-1255,798,9411,324,3791,83797.68%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1697.47%a
20252025-06-1883.79%b
20242024-06-1297.68%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this matter and, as a result, will have no effect on the outcome of Proposal No.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)21 : 1
CEO total compensation$11,393,602
Median employee compensation$540,474
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Matthew Shair, Ph.DIndependent · Departed during FY$39,489$199,928$200,004$0$200,000$639,421
Christy OligerIndependent · Audit · Newly elected27,715299,930300,0210—627,666
Ron SquarerIndependent · Nominating and Corporate Governance · Newly elected2,511299,984299,9570—602,452
Anna ProtopapasIndependent · Compensation85,500199,928200,0040—485,432
Sapna Srivastava, Ph.DIndependent · Audit (Chair)62,000199,928200,0040—461,932
Cameron A. Wheeler, Ph.DIndependent · Audit · Compensation54,830199,928200,0040—454,762
Michael L. Meyers, M.D., Ph.DIndependent · Nominating and Corporate Governance (Chair)52,000199,928200,0040—451,932
Grant C. BogleIndependent · Compensation (Chair)49,995199,928200,0040—449,927
Joseph Pearlberg, M.D., Ph.DIndependent · Nominating and Corporate Governance · Not standing for re-election47,000199,928200,0040—446,932
Gary Gilliland, M.D., Ph.DIndependent · Audit · Departed during FY24,285—297,9370—322,222
Emily Drabant Conley, Ph.DIndependent · Compensation · Departed during FY26,620—22,8790—49,499
Andrew A. F. Hack, M.D., Ph.DIndependent · Audit · Departed during FY24,285——0—24,285
James R. Porter, Ph.DEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer—
Annual equity retainer$425,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$496,230
Equity awards (grant-date value)$1,999,410
All other compensation$200,000
Total cost of the board$2,695,640

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Nuvalent names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Nuvalent.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Summit Therapeutics Inc.2025Mahkam Zanganeh$616,500$0$245,021,384$0$246,047,279
2Arcellx, Inc.2024Rami Elghandour653,2889,342,06910,850,151021,402,668
3Immunovant, Inc.2026Eric Venker636,618019,010,639020,158,767
4Madrigal Pharmaceuticals, Inc.2025Bill Sibold918,53112,297,8504,537,1461,438,81419,206,341
5Revolution Medicines, Inc.2025Mark Goldsmith812,5003,968,0768,995,114889,70014,672,390
6Vaxcyte, Inc.2025Grant Pickering800,0004,300,1598,714,048630,00014,458,937
7Cytokinetics, Incorporated2025Robert Blum853,0695,150,0195,095,918772,71511,881,456
8Nuvalent2025James Porter652,1004,392,5635,857,906469,51211,393,602
9Arrowhead Pharmaceuticals, Inc.2025Christopher Anzalone981,0466,810,29201,236,0009,029,861
10CRISPR Therapeutics AG2025Samarth Kulkarni768,6223,474,9002,768,862659,0937,678,477
11Denali Therapeutics Inc.2025Ryan Watts718,0001,151,8672,180,00304,751,515
—Avidity Biosciences, Inc.——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Nuvalent120%not disclosedNoAlpine Rewards
Arcellx, Inc.140%not disclosedNoMeridian Compensation Partners
Arrowhead Pharmaceuticals, Inc.125%PSU 70 · RSU 30not disclosedCompensia
Avidity Biosciences, Inc.not disclosednot disclosednot disclosednot disclosed
CRISPR Therapeutics AGnot disclosednot disclosednot disclosedAlpine Rewards, LLC
Cytokinetics, Incorporated120%RSU 50 · Options 50not disclosedAon Human Capital Solutions
Denali Therapeutics Inc.145%not disclosednot disclosedAlpine Rewards
Immunovant, Inc.110%not disclosedNoCompensia
Madrigal Pharmaceuticals, Inc.195%PSU 33 · RSU 33 · Options 33Yes — Relative TSR vs Nasdaq Biotechnology IndexCompensia
Revolution Medicines, Inc.146%Options 70 · RSU 30not disclosedCompensia
Summit Therapeutics Inc.105%Options 100not disclosednot disclosed
Vaxcyte, Inc.105%not disclosednot disclosedPay Governance

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Nuvalent in fiscal 2025?
As disclosed, James Porter (President and Chief Executive Officer) was the highest-paid executive at Nuvalent in fiscal 2025, with total compensation of $11,393,602.
How does Nuvalent's chief executive pay compare to its disclosed peer group?
As disclosed, James Porter's total compensation ranked at the 30th percentile of Nuvalent's disclosed peer group.
What is Nuvalent's CEO-to-median employee pay ratio?
As disclosed, Nuvalent's CEO-to-median employee pay ratio was 21:1.
How did shareholders vote on Nuvalent's executive compensation?
As disclosed, 97.47% of shareholders supported Nuvalent's executive compensation in the latest say-on-pay vote.
How much does Nuvalent spend in total on board compensation for fiscal 2025?
As disclosed, Nuvalent reported total board compensation of $2,695,640 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, James PorterDEF 14A2026-04-280001861560-26-000013Section “Summary Compen sation Table - 2025”. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247
2Section 01, Christopher TurnerDEF 14A2026-04-280001861560-26-000013Section “Summary Compen sation Table - 2025”. As printed: 4,239,298. Filing ↗machine: r5 · c14 · span 704965–704974
3Section 01, Alexandra BalcomDEF 14A2026-04-280001861560-26-000013Section “Summary Compen sation Table - 2025”. As printed: 4,170,614. Filing ↗machine: r8 · c14 · span 720674–720683
4Section 01, Darlene NociDEF 14A2026-04-280001861560-26-000013Section “Summary Compen sation Table - 2025”. As printed: 4,158,140. Filing ↗machine: r11 · c14 · span 736772–736781
5Section 01, Deborah MillerDEF 14A2026-04-280001861560-26-000013Section “Summary Compen sation Table - 2025”. As printed: 4,157,524. Filing ↗machine: r13 · c14 · span 747421–747430
6Section 03, James Porter RSUDEF 14A2026-04-280001861560-26-000013Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
7Section 03, Alexandra Balcom RSUDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r8 · c6 · span 717959–717968
8Section 03, Deborah Miller RSUDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r13 · c6 · span 744706–744715
9Section 03, James Porter OPTIONDEF 14A2026-04-280001861560-26-000013Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
10Section 03, Darlene Noci RSUDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r11 · c6 · span 733925–733934
11Section 03, Christopher Turner RSUDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r5 · c6 · span 702250–702259
12Section 03, Darlene Noci OPTIONDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r11 · c8 · span 734638–734647
13Section 03, Alexandra Balcom OPTIONDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r8 · c8 · span 718639–718648
14Section 03, Christopher Turner OPTIONDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r5 · c8 · span 702930–702939
15Section 03, Deborah Miller OPTIONDEF 14A2026-04-280001861560-26-000013Section “OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH” · grants of plan-based awards table. Filing ↗machine: t14 · r13 · c8 · span 745386–745395
16Section 07, pay ratioDEF 14A2026-04-280001861560-26-000013Section “CEO Pay Ratio”. As printed: 21 : 1. Filing ↗machine: span 1510190–1510192
17Section 08, Matthew Shair, Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 639,421. Filing ↗machine: span 390126–390334
18Section 08, Christy OligerDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 627,666. Filing ↗machine: t2 · r7 · c19 · span 367945–368153
19Section 08, Ron SquarerDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 602,452. Filing ↗machine: t2 · r11 · c19 · span 397606–397814
20Section 08, Anna ProtopapasDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 485,432. Filing ↗machine: t2 · r9 · c19 · span 382779–382987
21Section 08, Sapna Srivastava, Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 461,932. Filing ↗machine: span 404950–405158
22Section 08, Cameron A. Wheeler, Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 454,762. Filing ↗machine: span 412445–412653
23Section 08, Michael L. Meyers, M.D., Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 451,932. Filing ↗machine: span 360462–360670
24Section 08, Grant C. BogleDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 449,927. Filing ↗machine: t2 · r2 · c19 · span 330623–330831
25Section 08, Joseph Pearlberg, M.D., Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 446,932. Filing ↗machine: span 375443–375651
26Section 08, Gary Gilliland, M.D., Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 322,222. Filing ↗machine: span 345613–345821
27Section 08, Emily Drabant Conley, Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 49,499. Filing ↗machine: span 338118–338325
28Section 08, Andrew A. F. Hack, M.D., Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 24,285. Filing ↗machine: span 347609–347816
29Section 08, James R. Porter, Ph.DDEF 14A2026-04-280001861560-26-000013Section “Director Compensation”. As printed: 0. Filing ↗
30Section 02, James Porter 2026-05-04Form 42026-05-060001862900-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, James Porter 2026-05-04Form 42026-05-060001862900-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, James Porter 2026-05-04Form 42026-05-060001862900-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, James Porter 2026-05-04Form 42026-05-060001862900-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, James Porter 2026-05-04Form 42026-05-060001862900-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Darlene Noci 2026-05-28Form 42026-06-010001862148-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Deborah Miller 2026-05-28Form 42026-06-010001868741-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Deborah Miller 2026-05-28Form 42026-06-010001868741-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Deborah Miller 2026-05-28Form 42026-06-010001868741-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Darlene Noci 2026-05-28Form 42026-06-010001862148-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Darlene Noci 2026-05-28Form 42026-06-010001862148-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Deborah Miller 2026-05-28Form 42026-06-010001868741-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Deborah Miller 2026-05-28Form 42026-06-010001868741-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Deborah Miller 2026-05-28Form 42026-06-010001868741-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Darlene Noci 2026-05-28Form 42026-06-010001862148-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Darlene Noci 2026-05-28Form 42026-06-010001862148-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Darlene Noci 2026-05-28Form 42026-06-010001862148-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Darlene Noci 2026-05-28Form 42026-06-010001862148-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Alexandra Balcom 2026-06-01Form 42026-06-030001862147-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, James Porter 2026-06-08Form 42026-06-100001862900-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, James Porter 2026-06-08Form 42026-06-100001862900-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, James Porter 2026-06-08Form 42026-06-100001862900-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, James Porter 2026-06-08Form 42026-06-100001862900-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, James Porter 2026-06-08Form 42026-06-100001862900-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Darlene Noci 2026-06-09Form 42026-06-110001862148-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Darlene Noci 2026-06-09Form 42026-06-110001862148-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Darlene Noci 2026-06-09Form 42026-06-110001862148-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Darlene Noci 2026-06-09Form 42026-06-110001862148-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Darlene Noci 2026-06-09Form 42026-06-110001862148-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Darlene Noci 2026-06-09Form 42026-06-110001862148-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Darlene Noci 2026-06-09Form 42026-06-110001862148-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Grant C. Bogle 2026-06-16Form 42026-06-180001646675-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Michael L. Meyers 2026-06-16Form 42026-06-180001664204-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Christy Oliger 2026-06-16Form 42026-06-180001822092-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Anna Protopapas 2026-06-16Form 42026-06-180001347582-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Ron Squarer 2026-06-16Form 42026-06-180001454001-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Sapna Srivastava 2026-06-16Form 42026-06-180001569226-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Cameron Wheeler 2026-06-16Form 42026-06-180001735323-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, James E. Flynn 2026-06-16Form 42026-06-180001193805-26-000845Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Darlene Noci 2026-06-29Form 42026-07-010001862148-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Darlene Noci 2026-06-29Form 42026-07-010001862148-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Darlene Noci 2026-06-29Form 42026-07-010001862148-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Alexandra Balcom 2026-07-01Form 42026-07-060001862147-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Alexandra Balcom 2026-07-01Form 42026-07-060001862147-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Alexandra Balcom 2026-07-01Form 42026-07-060001862147-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Alexandra Balcom 2026-07-01Form 42026-07-060001862147-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Darlene Noci 2026-07-01Form 42026-07-060001862148-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Darlene Noci 2026-07-01Form 42026-07-060001862148-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Darlene Noci 2026-07-01Form 42026-07-060001862148-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Darlene Noci 2026-07-01Form 42026-07-060001862148-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Darlene Noci 2026-07-01Form 42026-07-060001862148-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Alexandra Balcom 2026-07-01Form 42026-07-060001862147-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, James Porter 2026-07-06Form 42026-07-080001862900-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, James Porter 2026-07-06Form 42026-07-080001862900-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, James Porter 2026-07-06Form 42026-07-080001862900-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Henry E. Pelish 2026-07-09Form 42026-07-100002029477-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Michael L. Meyers 2026-07-15Form 42026-07-150001193125-26-305095Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Michael L. Meyers 2026-07-15Form 42026-07-150001193125-26-305095Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Cameron Wheeler 2026-07-15Form 42026-07-150001193125-26-305050Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Grant C. Bogle 2026-07-15Form 42026-07-150001193125-26-305051Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Anna Protopapas 2026-07-15Form 42026-07-150001193125-26-305052Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Anna Protopapas 2026-07-15Form 42026-07-150001193125-26-305052Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Sapna Srivastava 2026-07-15Form 42026-07-150001193125-26-305082Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Cameron Wheeler 2026-07-15Form 42026-07-150001193125-26-305050Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Cameron Wheeler 2026-07-15Form 42026-07-150001193125-26-305050Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Cameron Wheeler 2026-07-15Form 42026-07-150001193125-26-305050Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Grant C. Bogle 2026-07-15Form 42026-07-150001193125-26-305051Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Grant C. Bogle 2026-07-15Form 42026-07-150001193125-26-305051Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Anna Protopapas 2026-07-15Form 42026-07-150001193125-26-305052Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Anna Protopapas 2026-07-15Form 42026-07-150001193125-26-305052Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Anna Protopapas 2026-07-15Form 42026-07-150001193125-26-305052Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Anna Protopapas 2026-07-15Form 42026-07-150001193125-26-305052Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Ron Squarer 2026-07-15Form 42026-07-150001193125-26-305080Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Ron Squarer 2026-07-15Form 42026-07-150001193125-26-305080Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Christy Oliger 2026-07-15Form 42026-07-150001193125-26-305081Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Christy Oliger 2026-07-15Form 42026-07-150001193125-26-305081Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Christy Oliger 2026-07-15Form 42026-07-150001193125-26-305081Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Sapna Srivastava 2026-07-15Form 42026-07-150001193125-26-305082Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Sapna Srivastava 2026-07-15Form 42026-07-150001193125-26-305082Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Sapna Srivastava 2026-07-15Form 42026-07-150001193125-26-305082Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Sapna Srivastava 2026-07-15Form 42026-07-150001193125-26-305082Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Sapna Srivastava 2026-07-15Form 42026-07-150001193125-26-305082Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Sapna Srivastava 2026-07-15Form 42026-07-150001193125-26-305082Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Michael L. Meyers 2026-07-15Form 42026-07-150001193125-26-305095Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Michael L. Meyers 2026-07-15Form 42026-07-150001193125-26-305095Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Michael L. Meyers 2026-07-15Form 42026-07-150001193125-26-305095Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Michael L. Meyers 2026-07-15Form 42026-07-150001193125-26-305095Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, Cameron Wheeler 2026-07-15Form 42026-07-150001193125-26-305050Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Cameron Wheeler 2026-07-15Form 42026-07-150001193125-26-305050Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, James E. Flynn 2026-07-15Form 42026-07-170001193805-26-000978Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Anna Protopapas 2026-07-15Form 42026-07-150001193125-26-305052Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Darlene Noci 2026-07-15Form 42026-07-150001193125-26-305072Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Alexandra Balcom 2026-07-15Form 42026-07-150001193125-26-305094Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, James Porter 2026-07-15Form 42026-07-150001193125-26-305059Insider equity transaction reported since the proxy statement. Filing ↗
221Section 02, Cameron Wheeler 2026-07-15Form 42026-07-150001193125-26-305050Insider equity transaction reported since the proxy statement. Filing ↗
222Section 02, Grant C. Bogle 2026-07-15Form 42026-07-150001193125-26-305051Insider equity transaction reported since the proxy statement. Filing ↗
223Section 02, Deborah Miller 2026-07-15Form 42026-07-150001193125-26-305058Insider equity transaction reported since the proxy statement. Filing ↗
224Section 02, Henry E. Pelish 2026-07-15Form 42026-07-150001193125-26-305062Insider equity transaction reported since the proxy statement. Filing ↗
225Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
226Section 02, Benjamin Lane 2026-07-15Form 42026-07-150001193125-26-305068Insider equity transaction reported since the proxy statement. Filing ↗
227Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
228Section 02, Christopher Turner 2026-07-15Form 42026-07-150001193125-26-305073Insider equity transaction reported since the proxy statement. Filing ↗
229Section 02, Michael L. Meyers 2026-07-15Form 42026-07-150001193125-26-305095Insider equity transaction reported since the proxy statement. Filing ↗
230Section 06, 2026 voteForm 8-K2026-06-180001861560-26-000023Item 5.07 · say-on-pay result. As reported: 97.47% (votes for as printed: 68,898,711). Filing ↗
231Section 06, 2025 voteForm 8-K2025-06-200000950170-25-088542Item 5.07 · say-on-pay result. As reported: 83.79% (votes for as printed: 53,520,192). Filing ↗
232Section 06, 2024 voteForm 8-K2024-06-140000950170-24-073632Item 5.07 · say-on-pay result. As reported: 97.68% (votes for as printed: 55,798,941). Filing ↗
233Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
234Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
235Section 09b board cost (computed)Computed——Cash 496,230 + equity 1,999,410 + all other 200,000 = 2,695,640, summed across the director compensation table rows.machine: formula: Σ = 2,695,640
236Summit Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-170001599298-26-000029CEO total compensation as printed in Summit Therapeutics Inc.'s own proxy. As printed: 246,047,279. Filing ↗machine: r6 · c21 · span 385284–385295
237Arcellx, Inc., Section 10b CEO totalDEF 14A2025-04-170001193125-25-084363CEO total compensation as printed in Arcellx, Inc.'s own proxy. As printed: 21,402,668. Filing ↗machine: r2 · c31 · span 471887–471897
238Immunovant, Inc., Section 10b CEO totalDEF 14A2026-07-220001764013-26-000092CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726
239Madrigal Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001308179-26-000352CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952
240Revolution Medicines, Inc., Section 10b CEO totalDEF 14A2026-04-270001193125-26-182453CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618
241Vaxcyte, Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173672CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207
242Cytokinetics, Incorporated, Section 10b CEO totalDEF 14A2026-04-170001140361-26-015364CEO total compensation as printed in Cytokinetics, Incorporated's own proxy. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103
243Nuvalent (subject), Section 10b CEO totalDEF 14A2026-04-280001861560-26-000013CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247
244Arrowhead Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-01-270000879407-26-000019CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484
245CRISPR Therapeutics AG, Section 10b CEO totalDEF 14A2026-04-210001193125-26-165158CEO total compensation as printed in CRISPR Therapeutics AG's own proxy. As printed: 7,678,477. Filing ↗machine: r2 · c25 · span 821649–821658
246Denali Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
247Section 10a, CRISPR Therapeutics AG reciprocityDEF 14A—0001193125-26-165158CRISPR Therapeutics AG's most recent proxy was read; its disclosed peer group does not include Nuvalent. Filing ↗
248Section 10a, Arcellx, Inc. reciprocityDEF 14A—0001193125-25-084363Arcellx, Inc.'s most recent proxy was read; its disclosed peer group does not include Nuvalent. Filing ↗
249Section 10a, Cytokinetics, Incorporated reciprocityDEF 14A—0001140361-26-015364Cytokinetics, Incorporated's most recent proxy was read; its disclosed peer group does not include Nuvalent. Filing ↗
250Section 10a, Immunovant, Inc. reciprocityDEF 14A—0001764013-26-000092Immunovant, Inc. names Nuvalent in its own disclosed peer group (read from its most recent proxy). Filing ↗
251Section 10a, Madrigal Pharmaceuticals, Inc. reciprocityDEF 14A—0001308179-26-000352Madrigal Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Nuvalent. Filing ↗
252Section 10a, Denali Therapeutics Inc. reciprocityDEF 14A—0001714899-26-000054Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Nuvalent. Filing ↗
253Section 10a, Arrowhead Pharmaceuticals, Inc. reciprocityDEF 14A—0000879407-26-000019Arrowhead Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Nuvalent. Filing ↗
254Section 10a, Revolution Medicines, Inc. reciprocityDEF 14A—0001193125-26-182453Revolution Medicines, Inc. names Nuvalent in its own disclosed peer group (read from its most recent proxy). Filing ↗
255Section 10a, Vaxcyte, Inc. reciprocityDEF 14A—0001193125-26-173672Vaxcyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Nuvalent. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.